Top Tweets for #GEJC
1L HER2-neg gastric/GEJC isn’t one bucket.
Biology splits into CLDN18.2 (targeted), CPS (IO), and dual-precision (CLDN18.2+PD-1).
ILUSTRO triplet shows the strongest signal in CLDN18.2-high.
#GastricCancer #GEJC #CLDN18 #PD1 #IO #ASCOGI #PrecisionOncology
ILUSTRO shows that dual-precision (CLDN18.2 + PD-1) may deepen 1L benefit in HER2-neg gastric/GEJC, especially in CLDN18.2-high. Phase 3 LUCERNA will test if it becomes a standard.
#GastricCancer #GEJC #CLDN18 #PD1 #IO #PrecisionOncology #ASCOGI #Oncology #ClinicalTrials
WELCOME To #ESMO25: The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER:
ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur
@acampsmalea
@BRicciutiMD
@yekeduz_emre
@HHorinouchi
@FadiHaddad_MD
@Abdallah81MD
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@bavilima
@realbowtiedoc
@Erman_Akkus
@Lucarecco
@GaiaGriguolo
@JankovicK
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@OscarTahuahua
@UOzkerim
@DrRishabhOnco
@Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi
@CathyEngMD
@marklewismd
@manjuggm
@stacy_hurt
@ARosen380
@KoheiShitara
@GillSharlene
@BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer See less
🔥 The @OncoAlert #GICancer Faculty proudly presents the🔝 🔟 #ESMO25 abstracts in #CRC, #HCC & #GEJC #ColonCancer
Get ready for the most exciting #GICancer 🆙dates coming from Berlin 🇩🇪! 😊
The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER: ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer
The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
✅ LBA10 :BEMARITUZUMAB PLUS CHEMOTHERAPY FOR ADVANCED OR METASTATIC FGFR2B OVEREXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FORTITUDE-101
✅2098M0
CADONILIMAB PLUS CHEMOTHERAPY VS. CHEMO AS FIRST-LINE TREATMENT FOR ADV.
GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: COMPASSION-15
✅LBA50
IMBRAVE152/SKYSCRAPER-14: FIRST-LINE TIRAGOLUMAB + ATEZOLIZUMAB + BEVACIZUMAB VS PLACEBO + ATEZO + BEV IN UNTREATED LOCALLY ADVANCED OR METASTATIC HCC
✅LBA51
IKF-035/ABC-HCC: ATEZOLIZUMAB PLUS BEVACIZUMAB VS. TRANSARTERIAL CHEMOEMBOLIZATION IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA
✅14700
PERIOPERATIVE CAMRELIZUMAB PLUS RIVOCERANIB IN RESECTABLE HCC (CARES-009)
✅LBA11
NEOADJUVANT TORIPALIMAB PLUS LENVATINIB AND GEMOX IN RESECTABLE, HIGH-RISK INTRAHEPATIC CHOLANGIOCARCINOMA
✅LBA30
ZANZALINTINIB PLUS ATEZOLIZUMAB VS REGORAFENIB IN PREVIOUSLY TREATED MET.
COLORECTAL CANCER: PRIMARY OS ANALYSIS FROM STELLAR-303 STUDY
✅BA9
CTDNA-GUIDED ADJUVANT CHEMOTHERAPY DE-ESCALATION IN STAGE III COLON CANCER: ANALYSIS OF THE CTDNA-NEGATIVE COHORT FROM THE RANDOMIZED AGITG DYNAMIC-I|I
✅LBA28
DESTINY-CRC02: TRASTUZUMAB DERUXTECAN (T-DXD) MONOTHERAPY (HER2+ MCRC)
✅LBA85
RESULTS OF A RANDOMIZED PHASE 3 TRIAL OF SHORT-COURSE VERSUS LONG-COURSE PREOPERATIVE CHEMOTHERAPY FOR STAGE I-III PANCREATIC DUCTAL ADENOCARCINOMA
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
OncoAlert GI faculty
@pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#gicancer
#gastrointestinalcancer
#colorectalcancer
#colorectalcancerawareness
#coloncancer
#stomachcancer
#livercancer
#esophagealcancer
#pancreaticcancer
First trial of CAR-T cell cancer treatment for solid tumor response - @ShandaBlackmon
https://t.co/N64rsXeYrx
#ASCO2025 #Cancer #CARTCellTreatment #GEJC #MedEd #MedX #OncoDaily #Oncology #Satricabtagene #Autoleucel
Discover how to implement molecular testing and #immunotherapy in #GastricCancer and #GEJC through real-world scenarios and case-based learning. https://t.co/gZUmviKyuH
Exciting advancements in #GastricCancer and #GEJC treatment! Hear expert guidance from Samuel Cytryn, MD, and Yelena Y. Janjigian, MD, on how molecular testing and #immunotherapy are reshaping care standards. Watch today to earn CME/MOC/AAPA/IPCE credit https://t.co/gZUmviKyuH
#News for #Investors and #Media: We’re proud to be presenting important new data at #ESMOGI2024 from two of our Phase 3 studies in esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer. #ESCC #GEJC
Our @giconnectInfo expert Dr. David Tougeron will present a poster at #ASCO2022! Phase-II study evaluating #FOLFIRI + #durvalumab and #FOLFIRI + #durvalumab + #tremelimumab in advanced #GC or #GEJC: #PRODIGE59-DURIGAST. 4th June 14:00 BST Poster 24!
https://t.co/4r5TRLOrZo
#MedEd
Our @giconnectInfo expert Dr. David Tougeron will present a poster at #ASCO2022! Phase-II study evaluating #FOLFIRI + #durvalumab and #FOLFIRI + #durvalumab + #tremelimumab in advanced #GC or #GEJC: #PRODIGE59-DURIGAST. 4th June 14:00 BST Poster 24!
https://t.co/3azkuv06qF
#MedEd
Data from the #ATTRACTION-4 study is available! Effects of #nivolumab in combination with #chemotherapy compared to placebo with #chemotherapy in HER2 -ve unresectable/recurrent #gastriccancer or #GEJC!
https://t.co/kYTSD1V4DB
#MedEd #GC #GEJC
@Yelito80419129 ...te Jelito ale kto to wszystko organizuje..?...moze wiesz bystrzaku...no i jeszcze po co..Żydzi odpadają w szurskich opowiesciach to kto.. #Reptilians #bigFarma #Gejc ..zaznacz własciwe.
Just 3 days until #ESMO21! @YJanjigianMD will present a late breaking abstract on #nivolumab + #chemotherapy vs. #ipilimumab + chemotherapy as #First-line treatment in #GC #GEJC and #EAC, results from the #CheckMate649 study! LBA7 19/09 https://t.co/0JoWWP8iqU
#MedEd @myESMO
@DocCatenacci on phase III JAVELIN Gastric 100 switch maintenance with #IO is not #SOC in metastatic #GEJC/GC but highlights the yin-yang effect of #OS curves w/IOs, can we accentuate the yang portion of the curve w/further enrichment by PD-L1? @CSCancerCare @Dan_Theodorescu
Last Seen Hashtags on Sotwe
momson() +filter:videos
Seen from Canada
ometv #reaction
Seen from Mexico
WINTER_IS_COMING
Seen from United States
momson() +filter:media()
Seen from United States
chavsluts
Seen from Netherlands
2017Oct30
Seen from United States
とりあえずタヒチ計画参加しようね〜
Seen from United States
صنعانيه
Seen from Spain
jaylapage10
Seen from Mexico
BubsyPawsonFire
Seen from Korea
Most Popular Users
Elon Musk 
@elonmusk
240.7M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.8M followers
Taylor Swift
@taylorswift13
81.7M followers
Lady Gaga
@ladygaga
73.2M followers
Virat Kohli
@imvkohli
70.2M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
60.9M followers
X
@x
60.8M followers